Swipe Left For English News
1
获国际权威评级机构MSCI ESG最高AAA评级
2
引领绿色生物药发展，技术创新赋能健康未来
3
赋能全球客户迈向ESG发展新高度
上海,
2025年6月20日
全球领先的合同研究、开发和生产CRDMO服务公司药明生物（WuXi Biologics, 2269.HK）宣布其入选明晟公司（MSCI）2025年精选指数。公司连续三年获此殊荣，彰显了全球资本市场对其可持续发展承诺及生物制药行业领导者的认可。
MSCI精选指数旨在甄选各行业中ESG评级表现卓越的企业，为机构投资者提供可持续发展投资标的、投资追踪提供依据。据MSCI数据，挂钩MSCI 可持续与气候变化指数的ETF数量和管理规模在全球可持续与气候ETF市场中位居第一。凭借在产品安全与质量、人才发展、公司治理与行为规范、气候变化等关键议题上的出色表现，药明生物自2023年起连续获得MSCI授予的最高AAA评级。
陈智胜博士
首席执行官
ESG委员会主席
药明生物
我们很荣幸再次入选MSCI精选指数，这是对公司在可持续发展领域持续精进的肯定和认可。作为绿色生物药解决方案领域的全球领导者，我们始终秉持卓越的ESG理念，并赋能全球合作伙伴，助力其迈向ESG发展新高度，共同推动整个价值链的可持续发展。
作为联合国全球契约组织（UNGC）和制药供应链倡议组织（PSCI）成员，药明生物凭借出色的表现获得了权威评级机构的广泛认可。公司连续两年获得EcoVadis“铂金”评级、入选道琼斯可持续发展指数（DJSI）、CDP水安全管理A级榜单、CDP气候变化A-领导力评分；连续五年获评晨星Sustainalytics ESG“行业最高评级”及“区域最高评级”；入选富时社会责任指数系列及恒生ESG 50指数，获得ISS ESG评级“最佳”奖章认可等，充分彰显了公司在可持续发展领域的卓越表现。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年12月底，药明生物帮助客户研发和生产的综合项目高达817个，其中包括21个商业化生产项目（不包括新冠项目）。
药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
MSCI声明
将药明生物纳入任何MSCI指数，以及在其中使用MSCI标识、商标、服务标记或指数名称，并不构成MSCI或其任何附属机构对药明生物的赞助、认可或宣传。MSCI 指数是 MSCI 的专有财产。MSCI及MSCI指数名称和标识是MSCI或其附属机构的商标或服务标志。
WuXi Biologics Included in MSCI Selection Indexes for Third Consecutive Year
1
Recognized by MSCI with AAA ESG Rating
2
Leader in Green CRDMO solutions for a healthier future
3
Empowering global clients to fulfill their sustainability commitments
Shanghai,
June 20, 2025
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in 2025 MSCI Selection Indexes for the third consecutive year, underscoring continued recognition from global capital markets of the company's sustainability commitment, as well as its leadership in the biopharmaceutical industry.
The MSCI Selection Indexes are designed to reflect the performance of companies with high ESG ratings relative to their sector peers. They are built for institutional investors seeking exposure to companies with a strong sustainability profile and a relatively low tracking error in relation to the underlying equity market. According to MSCI, the number of ETFs and ETF assets linked to MSCI Sustainability and Climate Change indexes ranks the top globally among others. WuXi Biologics — with outstanding performance in areas of Product Safety and Quality, Human Capital Development, Corporate Governance and Corporate Behavior, and Climate Change —has been granted MSCI's highest AAA rating each year since 2023.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are very pleased to once again be selected for the MSCI Selection Indexes, a testament of our continued dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable clients worldwide to fulfill their ESG commitments, and work with all stakeholders to promote responsible practices throughout the entire value chain.
As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability and has earned widespread recognitions for its efforts. The company was awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A list" and awarded an A- CDP Climate Change leadership-level score for two consecutive years; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
MSCI Disclaimer
The inclusion of WuXi Biologics in any MSCI index, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement or promotion of WuXi Biologics by MSCI or any of its affiliates. The MSCI indexes are the exclusive property of MSCI. MSCI and the MSCI index names and logos are trademarks or service marks of MSCI or its affiliates.
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间收到药明生物最新消息
